deltatrials

Stage iv lung cancer ajcc v8 Trials in Duarte, United States

Conditions / Stage iv lung cancer ajcc v8 / Duarte, United States

Clinical trials for Stage iv lung cancer ajcc v8 investigate a range of treatment strategies and patient populations.

22 total trials for this combination

Showing top 10 of 22 trials

Trials

NCT ID Title Status Phase
NCT03971474 Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) COMPLETED PHASE2
NCT04588246 Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery TERMINATED PHASE3
NCT06500455 Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain RECRUITING PHASE3
NCT06616584 Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) RECRUITING PHASE2/PHASE3
NCT04625647 Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) ACTIVE_NOT_RECRUITING PHASE2
NCT06287775 Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer RECRUITING
NCT04929041 Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative SUSPENDED PHASE2/PHASE3
NCT05633602 Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study ACTIVE_NOT_RECRUITING
NCT04250545 Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer ACTIVE_NOT_RECRUITING
NCT03845296 Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) COMPLETED PHASE2

Related Pages